Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 8/20 | 1.00 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.76 |
| ▸ | PDGFRB | P09619 | 10/20 | 0.73 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.73 |
| ▸ | KDR | P35968 | 9/20 | 0.73 |
| ▸ | EGFR | P00533 | 4/20 | 0.62 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.55 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5727887 | 1.00 | AKT2 (1.00) | AKT2ZAP70PDGFRBFGFR1KDR | |
| SCHEMBL5728007 | 0.87 | AKT2 (0.77) | AKT2ZAP70PDGFRBFGFR1KDR | |
| SCHEMBL5728004 | 0.87 | AKT2 (0.77) | AKT2ZAP70PDGFRBFGFR1KDR | |
| SCHEMBL4414158 | 0.86 | ZAP70 (1.00) | AKT2ZAP70PDGFRBFGFR1KDR | |
| SCHEMBL4414161 | 0.86 | ZAP70 (1.00) | AKT2ZAP70PDGFRBFGFR1KDR | |
| SCHEMBL4407137 | 0.86 | PDGFRB (0.81) | AKT2ZAP70PDGFRBFGFR1KDR | |
| SCHEMBL4407140 | 0.86 | PDGFRB (0.81) | AKT2ZAP70PDGFRBFGFR1KDR | |
| SCHEMBL5728036 | 0.85 | AKT2 (0.74) | AKT2ZAP70PDGFRBFGFR1KDR | |
| SCHEMBL5728046 | 0.85 | AKT2 (0.74) | AKT2ZAP70PDGFRBFGFR1KDR | |
| SCHEMBL4414661 | 0.85 | PDGFRB (0.80) | AKT2ZAP70PDGFRBFGFR1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680401-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | Schering Aktiengesellschaft (DE) | 2006-07-19 | — | — | EP | claimed |
| WO-2005040116-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-06 | — | — | WO | claimed |
| US-20050090541-A1 | Indolinone derivatives and their use in treating disease-states such as cancer | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-04-28 | — | — | US | claimed |
| US-7105563-B2 | Indolinone derivatives and their use in treating disease-states such as cancer | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-09-12 | — | — | US | disclosed |
| EP-1680401-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | Schering Aktiengesellschaft (DE) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005040116-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-06 | — | — | WO | disclosed |
| US-20050090541-A1 | Indolinone derivatives and their use in treating disease-states such as cancer | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090541-A1 | Indolinone derivatives and their use in treating disease-states such as cancer | PDK3, PDK2, PDK4 | AKT2 1359/4885ZAP70 3279/4885PDGFRB 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.